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Abstract The aim of this retrospective study was to
provide data on the clinical features and treatment out-
comes of patients with NDPH (fulfilling Kung et al.’s
criteria). A total of 63 patients were observed during a 5-yr
period (2007–2012). More than one-third (35 %) patients
had migrainous features; 65 % patients fulfilled the ICHD-
II criteria. Both groups were similar in most clinical and
epidemiological features. However, migrainous features
were more common in patients with a prior history of
episodic migraine (though statistically not significant).
After a median follow-up of 9 months, 37 % patients
showed ‘‘excellent’’ response (no or less than 1 headache
per month). Another 30 % patients had ‘‘good’’ response
([50 % reduction in headache frequency or days per
month). Excellent response was more in patients with a
history of less than 6 months duration (statistically not
significant). Patients with a recognized trigger showed
better prognosis. Response was better in patients who
received intravenous therapy of methyl prednisolone and
sodium valproate. We suggest prospective and controlled
studies to confirm our observations.
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Introduction
More than 25 years have passed since the first description
of new daily persistent headache (NDPH) by Vanast [1].
However, its clinical features and natural history are still
being determined [2, 3]. The International Headache
Society (IHS) proposed a diagnostic criterion in the second
edition of the International Classification of Headache
Disorders (ICHD-II) [4]. However, a few authors suggest
that current ICHD-II criteria for NDPH are too restrictive,
and a few new criteria have been suggested in the recent
past in the literature [2, 3]. The main characteristic feature
of NDPH is daily and unremitting headache from the onset
or from less than 3 days from the onset [4]. The ICHD-II
criterion for NDPH resembles daily form of chronic ten-
sion-type headache (CTTH) that begins abruptly [4].
The main controversy in the diagnostic criteria is
regarding the presence of migrainous features [5]. ICHD-II
acknowledges only one of photophobia, phonophobia, or
mild nausea in primary NDPH. However, most other
migrainous features are against the diagnosis of NDPH.
Unilateral head pain, throbbing headache, severe intensity,
exacerbations by physical activities, moderate to severe
nausea, and vomiting are not the features of NDPH.
However, most studies suggest that migrainous features
may be the part of the clinical spectrum of NDPH or a
clinical sub form of NDPH exists [6–9]. Initially, NDPH
was considered as a ‘‘benign or self-limiting’’ form of
headache. But, recent observations suggest that it may be
the most treatment refractory of all primary headache
disorders.
In this retrospective study, we studied a group of con-
secutive patients who fulfilled the Kung et al.’s revised
criteria for NDPH. We mainly looked for the clinical fea-
tures and treatment responsiveness in these patients.
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Materials and methods
This study was conducted as a retrospective chart review of
patients seen in Neurology Department in our institute (a ter-
tiary centre) from January 2007 to February 2012. The study
constitutes a consecutive series of patients who were diagnosed
as having NDPH. NDPH was diagnosed according to the
revised ICHD-II criteria (Kung et al.’s criteria). Most recent
studies on NDPH have used this criterion. Kung et al.’s criteria
include only criteria A and B of ICHD-II. It reads as
(A) headache more than 3 months, and (B) headache is daily
and unremitting from onset or less than 3 days from onset.
Patients with a history of episodic migraine or episodic tension-
type headache (B1 attack/month) were included in the study.
We reviewed each individual’s chart with the diagnosis of
NDPH. If the chart was not complete then the patient was
interviewed by phone to retrieve the missing information. Age
and duration of illness were determined as of the date of first
visit. The patients who did not have headache duration of
[3 months at the time of first visit were excluded from the
study. We also recorded the medications used and their
responses. As there are no well-defined guidelines in the lit-
erature for the treatment of NDPH, the treatment strategy was
not standardized and the treatment plans were made at the
discretion of the treating physician. The follow-up clinical
response was rated by the treating physician as: Excellent (no
or less than 1 headache per month), Good ([50 % reduction
in headache frequency or days per month), Fair (\50 %
reduction in headache frequency or days per month), and Poor
(Minimal or no response).
Exclusion criteria included (a) a possible secondary NDPH;
(b) patients who were never subjected for neuroimaging, as we
did not rule out the possibility of secondary NDPH in these
patients; and (c) a follow-up of\3-months duration.
The majority of patients were seen and examined by a
neurologist who has a special interest in headache disor-
ders. A neurological examination including fundoscopy
was performed on all patients. The study did not require
approval by the local ethics committee as per the local
regulations for retrospective observation. Patients who
reported earlier to our institute were included to complete
the data.
Data are presented as percentage or as arithmetic mean
with SD. Student’s t test was used to compare the contin-
uous data. The Fisher-exact test was used for categorical
data. All p values were two-tailed, and a p value\0.05 was
defined as statistically significant.
Results
We identified 69 patients with a diagnosis of NDPH. Three
patients were excluded because of the possibility of
secondary NDPH (2 patients: benign intracranial hyper-
tension, 1: brain tuberculoma). Two patients were excluded
as they were never subjected to cranial neuroimaging. One
more patient was excluded because of incomplete follow-up
(\3 months). Finally 63 patients were identified who ful-
filled the Kung et al.’s criteria for NDPH. Forty-one patients
(65 %) fulfilled the IHS criteria for HC (NDPH-ICHD).
Twenty-two patients (35 %) had prominent migrainous
features. We labeled this group as NDPH-mf (migrainous
features) (as suggested by Robbins et al.’s). Epidemiolog-
ical and clinical features are summarized in Table 1.
Patients subgroup (NDPH-ICHD and NDPH-mf) were
compared using Fisher exact (2-tailed).
Epidemiological and clinical features (Table 1)
Age of onset ranged from 18 to 68 years (mean 36.8 ±
12.8 years). 57 % patients were female. The average time
between the onset of the symptoms and the first visit to our
institute was 27.5 months (± 19.6 months). Twenty-seven
patients (43 %) had headache duration of more than
2 years at the time of first consultation and 12 patients
(19 %) had duration of B6 months (Table 3). The pain was
continuous since onset in all the patients. However, only
33 % patients were able to recall the exact day their
headache started. There were no statistically significant
differences in any parameter between the groups except
the migrainous features (which were the differentiating
points between the groups) (Table 1). Side-locked pain,
nausea, vomiting, photophobia, and phonophobia were
more in NDPH-mf. These all symptoms were statistically
significant. Side-locked migraine, hemicrania continua,
and other strictly unilateral headaches were excluded
carefully in patients with unilateral head pain. All patients
with unilateral headache (11 patients) received an indo-
methacin trial. None of the patients showed complete or
marked response to indomethacin. Although we could not
rule out the possibility of indomethacin resistant head-
aches, it seems less likely as typical exacerbations and
autonomic features were not noted in these patients.
All patients had daily headaches. However, Seven
patients (11 %) (five patients in NDPH-ICHD and two in
ICHD-mf groups) had pain-free period in a day on a few
occasions in a month. All patients had non-throbbing
base line pain. More than 50 % patients had throbbing
headaches during the exacerbations. Throbbing pain
during the exacerbation was more in NDPH-mf than
NDPH-ICHD (64 vs. 54 %). However, it was statistically
not significant. Aggravation by physical activities was
also more common in NDPH-mf than NDPH-ICHD (32
vs. 24 %) (statistically non-significant). Overall, 14 %
patients reported cranial autonomic feature (either con-
junctival injection or tearing), with slight preponderance
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in NDPH-mf group (23 vs. 9 %). None of the patients
reported auras.
Triggers
Overall, 54 % patients remembered a trigger, without any
differences between NDPH-mf and NDPH-ICHD (55 vs.
54 %). The most common trigger was infection (especially
respiratory tract infection). Overall, 29 % patients corre-
lated the onset of headache to the infection. Injury, stress,
and surgery were other triggers. Injury (mainly fall) was
reported as a trigger by seven (11 %) patients. Three
patients had fallen from height. Two patients had slipped
down while walking down a stairs. Another two patients
were assaulted manually. Three of them had mild head
trauma. As the injury was mild, none of them was inves-
tigated for the injury.
Prior history of headaches
A past history of headache was noted in 54 % patients
(29 % tension-type headache and 25 % migraine). No
patient had a past history of chronic daily headache (CDH)
or escalation of headache frequency prior to the onset of
Table 1 Epidemiological profiles and clinical features in NDPH (Kung et al.’s), NDPH (ICHD-II) and NDPH (mf)
NDPH (Kung et al.’s), n (%) NDPH (ICHD-II), n (%) NDPH-mf, n (%) p value
No. of patients 63 41 (65 %) 22 (35 %)
Age (years) (mean, range) 36.8 ± 12.8, 18–68 35.2 ± 11.5, 18–58 39.9 ± 14.1, 20–68 0.1585
Gender (female) 36 (57 %) 24 (59) 12 (55 %) 0.7946
Duration of illness
Mean (SD) 27.5 ± 19.6 months 25.14 ± 19.4 months 29.7 ± 19.9 months 0.3774
Range 3–72 months 4–60 months 3–60 months
Past history of TTH 18 (29) 13 (32) 5 (23) 0.5642
Past history of migraine 16 (25) 9 (22) 7 (32) 0.5446
Recalling onset day 21 (33) 14 (34) 7 (32) 1.000
Unilateral pain 11 (17) 4 (9) 7 (32) 0.0394*
Daily pain 63 (100) 41 (100) 22 (100) 1.000
Pain free period in a day 7 (11) 5 (12) 2 (9) 1.000
Type of pain
Non-throbbing 63 (100) 41 (100) 22 (100) 1.000
Throbbing 32 (51) 18 (54) 14 (64) 0.1877
Aggravation by physical activities 17 (27) 10 (24) 7 (32) 0.5619
Hampering routine activities/professional work 5 (8) 3 (7) 2 (9) 1.000
Associated features
Nausea 31 (49) 12 (29) 19 (86) 0.0001*
Vomiting 3 (5) 0 (0) 3 (14) 0.0388*
Photophobia 21 (33) 7 (17) 14 (64) 0.0005*
Phonophobia 12 (19) 3 (7) 9 (41) 0.0025*
Autonomic symptoms
Conjunctival-injection/tearing 9 (14) 4 (9) 5 (23) 0.2564
Depression (self-reported) 12 (19) 8 (20) 4 (18) 1.000
Anxiety (self-reported) 10 (16) 7 (17) 3 (14) 1.000
Triggering factors
None 29 (46) 19 (46) 10 (45) 1.000
Infection 18 (29) 10 (24) 8 (36) 0.3850
Injury 7 (11) 4 (9) 3 (14) 0.6871
Stress 5 (8) 5 (12) – 0.1530
Surgery 3 (5) 2 (5) 1 (5) 1.000
Post-partum 1 (2) 1 (2) – 1.000
Medication Overused 8 (13) 5 (12) 3 (14) 1.000
NDPH (ICHD-II) new daily persistent headache according to second edition of the International Classification of Headache Disorders, NDPH-mf
new daily persistent headache with prominent migrainous features, TTH tension-type headache
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NDPH. We compared NDPH with a past history headache to
NDPH with no such history of headache (Table 2). Migrainous
features (such as throbbing headache, nausea, vomiting, pho-
tophobia, phonophobia, and aggravation by physical activities)
were more common in NDPH with a past history of migraine.
Cranial autonomic features were also more common in patients
with NDPS-mf (25 vs. 6 %). However, none of these features
were statistically significant.
Investigations
The neurological and general examination (including fun-
doscopy) did not reveal any other abnormality in any
patient. All patients underwent neuroimaging. Fifty-seven
patients (90 %) had a brain MRI, and the remaining six
patients (10 %) had a head CT scan. Of the 57 MRI brain,
34 patients (54 %) had contrast enhanced MRI scan. Ten
patients (16 %) were subjected to magnetic resonance
venography. Neuruoimaging studies were essentially nor-
mal or were not casually related in any patient. Fourteen
patients (22 %) were subjected to lumbar punctures. All
had normal opening pressure. Cerebrospinal fluid (CSF)
examinations were normal except the presence of mild
pleocytosis (\10 lymphocytes/mm3) in three patients and a
slightly elevated protein (50 mg/dl) in one patient.
Treatment and follow-up
As there are no guidelines for the management in patients
with NDPH, treatment was not standardized. All patients
received medications. The treatment for most patients
was a combination of various drugs. The most preferred
treatment was a combination of steroid (intravenous methyl
prednisolone followed by oral therapy) ? sodium valproate
(intravenous followed by oral) ? antidepressant (amitrip-
tyline or dothiepin) ± naprosyn (250–500 b.i.d). Steroid
was given in the form of intravenous methyl prednisolone
(IV MPS) (500–1,000 mg daily for 3–5 days), followed by
oral steroid (prednisolone 1 mg/kg body wt) for 7–10 days.
Sodium valproate was initially given in the intravenous
form at the dose 15 mg/kg body weight (loading), followed
by 5 mg/kg 8 hourly for 3–5 days. Intravenous sodium
valproate was followed by oral valproate (500–1,500 mg/
daily) for 3–12 months (depending on the patients’ symp-
toms). Antidepressant was also given for 3–12 months
(amitriptyline 25–75 mg/daily or dothiepin 25–75 m/daily).
Naprosyn was given at the dose of 250–500 mg b.i.d for
1–3 weeks. This combination of the drugs was based on our
clinical experiences and the suggested treatment for the
other chronic daily headaches in the literature. Other com-
monly used drugs were topiramate, propranolol, flunarizine
and leviteracetam. The duration of the treatment for the
patients with CDH is not well defined. Doddick [10] sug-
gests that medication should be continued for at least
3–6 months until the patient gets a satisfactory response.
We follow this recommendation and gave therapy for at
least 3–6 months after achieving the target response. The
response rate to the drugs was calculated at the end of the
follow-up. The mean follow-up period was 9.3 ±
4.6 months. Earlier we reported nine patients with
Table 2 Comparison of clinical features of NDPH (Kung et al.’s) in patients with and without past history of headache
NDPH (with past history
of TTH) (n = 18)
NDPH (with past history
of migraine) (n = 16)
NDPH (with past history
of no headache) (n = 29)
Gender (female) 12 (67 %) 9 (56 %) 15 (52 %)
Duration of illness
Mean (SD) 27.2 ± 20.1 months 29.0 ± 18.8 months 28.0 ± 20.3 months
Range (months) 3–72 4–60 4–72
Unilateral pain 5 (28) 2 (13) 4 (14)
Type of pain
Non-throbbing 18 (100) 16 (100) 29 (100)
Throbbing 6 (33) 8 (50) 17 (59)
Aggravation by physical activities 3 (17) 4 (25) 3 (10)
Hampering routine activities 2 (11) 1 (6) 1 (3)
Associated features
Nausea 8 (44) 12 (75) 10 (34)
Vomiting 0 (0) 1 (6) 3 (10)
Photophobia 6 (33) 7 (44) 9 (29)
Phonophobia 4 (22) 7 (44) 6 (21)
Autonomic symptoms 1 (6) 4 (25) 3 (10)
NDPH new daily persistent headache according to second edition of the International Classification of Headache Disorders, TTH Tension type
headache
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post-infectious headache of shorter duration (6–20 weeks)
who showed a response to intravenous methyl prednisolone
[11]. However, only four had headache duration of
[3 months. In order to assess the treatment, we divided the
patients into three groups: (1) NDPH with 3–6 months of
duration, (2) NDPH with [6–24 months duration, and (3)
NDPH with [24 months duration (Table 3). Overall, 23
patients (37 %) showed an excellent response. The excel-
lent response was highest (58 %) in patients with NDPH of
3- to 6-months duration. However, only 26 % with NDPH
of more than 2-years duration showed a complete response.
Overall, nine patients (14 %) still had daily persistent
headache. Six of the 27 patients (22 %) with NDPH of[2-
years duration had poor response to drugs (minimal or no
response). 83 % patients with a history of less than
6-months durations had either Excellent or Good prognosis.
However, none of these data were statistically significant in
comparison to other groups.
The combination of IV MPS ? intravenous sodium
valproate ? antidepressant (amitriptyline or dothiepin) ±
naprosyn was given to 37 patients. The clinical responses
in these 37 patients were: Excellent, 17 (46 %); Good, 11
(30 %); Fair, 6 (16 %); and poor response, 3 patients
(8 %). We compared the treatment response of the patients
receiving this combination to the patients who did not
receive this combination (data not shown). Although, none
of the values reaches the statistically significant, the
response was more favorable in the patients receiving
combination therapy (46 vs. 19 % for excellent response).
Response to the drugs started on 2–5th day of the intra-
venous therapy and maximum improvement was achieved
in 2–6 weeks. A few patients (10 patients) received cycle
of IV MPS on two or more occasions (nine patients: 2
times; one patient: 3 times). Four patients received another
cycle because of poor response after first therapy (after
2–3 months). There was improvement in headache symp-
toms in three patients (grade of improvement changed from
poor response to ‘‘Good’’ response). Another two patients
received second cycle of IV MPS because of the incom-
plete response (both showed improvement). Four patients
received second cycle because of the recurrence of symp-
toms. These all patients showed ‘‘excellent’’ response to
second cycle.
No serious side effects were noted. Two patients com-
plained about Cushingoid symptoms (especially facial
edema). Two patients had pain abdomen. Three patients
developed leucocytosis that returned to normal in
7–10 days. All patients had normal blood pressures during
the hospitalization for the intravenous therapy.
Medication overuse was noted in eight patients. Five out
of these eight patients had headache of [2-years duration.
Other five patients had headache of 6- to 24-months
duration. The responses to treatment in these patients
were: Excellent, 2; Good, 3; Fair, 1; and poor response, 2
patients.
We also compared the treatment response in patients
having triggers to that of without triggers (Table 4).
Patients with a recognized trigger showed better prognosis.
Excellent response was about two times higher in patients
with a known trigger (47 vs. 24 %). However, it was sta-
tistically not significant (p value 0.0714). Sixteen patients
(out of 34) with a known trigger showed excellent
response. The patients with a preceding history of infection
showed more favorable response. There were 18 patients
with the preceding history of infections, 12 of them (67 %)
showed excellent response.
Table 3 Therapeutic responses according to the duration of the illness
NDPH (All
patients)











Excellent (no or less than one
headache per month), n (%)
23 (37 %) 7 (58 %) 9 (38 %) 7 (26 %) 0.16
Good ([50 % reduction in headache
frequency or days per month) n (%)
19 (30 %) 3 (25 %) 7 (29 %) 9 (33 %) 0.87
Fair (\50 % reduction in headache
frequency or days per month)
12 (19 %) 2 (17 %) 5 (21 %) 5 (19 %) 1.0
Poor (Minimal or no response). 9 (14 %) 0 (0 %) 3 (12 %) 6 (22 %) 0.23
Table 4 Therapeutic responses in NDPH patients with recognized








Excellent, n (%) 7 (24 %) 16 (47 %) 0.0714
Good, n (%) 10 (34 %) 9 (26 %) 0.5855
Fair, n (%) 6 (21 %) 6 (18 %) 1.0
Poor, n (%) 6 (21 %) 3 (9 %) 0.2804
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Discussion
The present diagnostic criteria of NDPH (of ICHD-II)
exclude the prominent migrainous features in NDPH.
There were very few case series of NDPH before the
introduction of ICHD criteria of NDPH [1, 7, 12]. How-
ever, these all case series had patients with prominent
migrainous features. Even after the development of ICHD
criteria for NDPH, most authors bypassed it and used
broader set of criteria which includes migrainous features
[2, 3, 6, 8, 9, 11]. In this retrospective study, we examined
the patients fulfilling the Kung et al.’s criteria for NDPH,
which allows to include migrainous features. Our study is
probably the third largest case series on NDPH (after Robin
et al.’s and Peng et al.’s observations).
In our cohort, about two-thirds of patients (65 %) ful-
filled the IHS criteria for NDPH. Twenty-two patients
(35 %) had prominent migrainous features (NDPH-mf). In
similar observation in other larger cohorts, 34–44 %
patients had fulfilled the criteria for NDPH-ICHD [2, 3, 9].
Epidemiological and clinical features of these two groups
were substantially similar, except the presence of migrain-
ous features in NDPH-mf, which were the differentiating
features between two. There were statistically significant
differences for unilateral pain, nausea, vomiting, photo-
phobia, and phonophobia.
Rozen [5] reviewed the literature for the presence of
migrainous features in patients with NDPH. The prevalence
for nausea in patients with NDPH was 33–68 %. Our 49 %
patients reported nausea. Takese et al. [13] used the strict
ICHD criteria to include NDPH patients and in that series
photophobia was noted by only 3 % patients, while none of
the patients had phonophobia. However, in other series both
photophobia and phonophobia were common (photophobia
27–66 % and phonophobia 17–61 %). The prevalence
of photophobia (33 %) and phonophobia (19 %) in our case
series was toward the lower side of the existing range.
In original description of NDPH (Vanast case series) [1],
patients did not have a prior history of headache. However,
most other series on NDPH had patients with a prior history
of headache. Robbins et al. [3] included only those patients
who had headache frequency of\4 per month. In Peng et al.
series [2], headache frequency was B1/month. In our
observation, more than half (54 %) had a history of episodic
headache (B1/month). Comparison between patients with
NDPH with past history of episodic tension-type headache
and NDPH with past history of migraine was done
(Table 2). Migrainous features and cranial autonomic fea-
tures were more common in NDPH with the past history of
migraine. Although, none of these features were statistically
significant, such observations (high migrainous features and
cranial autonomic features in patients with a past history of
episodic migraine) have not been observed previously in
any case series. This observation indicates that NDPH
patients with a past history of episodic migraine may have
more migrainous features. There may be several explana-
tions for this association. As migrainous features may be the
part of NDPH, this co-association is a normal phenomenon.
This might also be because of superimposed attacks of
migraine attacks in these patients. Although, no patients had
escalation of frequency of migraine just prior to NDPH
onset, we cannot rule out the possibility of abrupt transition
of episodic migraine into chronic migraine in these patients,
as about 20–30 % patients with CDH may have history of
abrupt transition from episodic migraine into chronic
migraine [12, 14]. There is no guideline to differentiate
NDPH with migrainous features to chronic (daily) migraine
with a history of abrupt transition from episodic headache to
chronic headache.
We reviewed the literature to delineate the interrelation
between the prior history of headache and migrainous
features (nausea, photophobia, phonophobia). Most studies
included migrainous features in their criteria. Prior history
of headaches was noted between 25 and 38 % [2, 3, 7, 8] in
these case series. Only one large series strictly followed
ICHD criteria (excluding migrainous features) [13]. Nau-
sea was reported by 33 % patients. However, photophobia
was noted by only 3 % patients. None of the patients had
phonophobia. The prior history of headache was noted in
only 7 % patients in that series. Therefore, a possibility
exists that a patient with a past history of episodic headache
might have more migrainous symptoms. Moreover,
patients with a past history of episodic migraine might have
attacks of migraine even on the background of NDPH. This
suggests that the presence of prominent migrainous fea-
tures should be judged cautiously in patients with a past
history of episodic headache (especially migraine).
Therapeutic responses and prognosis
The first description of NDPH considered this entity as a
‘‘benign or self-limiting’’ form of headache [1]; however,
most other observations considered it as the most refractory
headache disorder. A review of the literature suggests that
most studies were done on the patients who had headache
duration of more than 6 months. It may be the reason for
getting more refractory form of NDPH [15]. It is observed
that CDH with daily pain is more treatment refractory than
CDH without daily pain [16]. Patients with NDPH have
‘daily and continuous’ headache from the onset. Therefore,
a possibility to become refractory to treatment is more with
NDPH than any other CDH. A recent study done on patients
with shorter duration (median 5 months) had demonstrated
a relatively good prognosis [2]. Mean duration of illness in
our case series was 27.5 months. However, our patients
showed favorable out come. 37 % patients showed
482 J Headache Pain (2012) 13:477–485
123
‘‘excellent’’ response (no or less than 1 headache per
month). Another 30 % patients had ‘‘good’’ response
([50 % reduction in headache frequency or days per
month). Only 14 % patients had poor response. We cate-
gorized the patient in three groups to assess the response to
treatment: NDPH (3–6 months), NDPH ([6–24 months),
and NDPH ([24 months). We compared the response to
treatment between the groups. Although, none of the values
reach the statistical significance, patients with shorter duration
(at the time of first visit) had better outcome. Excellent
response was more than two times higher in patients with a
history of less than 6 months in comparison to patients with
history of[2 years (58 vs. 26 %). Although, a possibility of
self-limiting form of NDPH cannot be ruled out in patients
with NDPH of shorter duration (\6 months), our observations
indicate that intervention in early stage could prevent chro-
nification. However, a number of other explanations are also
plausible. A possibility of self-limiting form is more in
patients with headache of shorter duration. In the same line,
chance of being refractory to the treatment is more in patients
with history of longer duration. These all may be reasons for
the good responses in patients with shorter duration.
There is no specific treatment strategy for NDPH [5, 17].
On this issue Rozan [5] writes ‘‘Most headache specialists
will treat NDPH with the same acute and preventive
medications that they use to treat chronic migraine….’’
Unfortunately, there is no formal evidence-based recom-
mendation for optimal therapy in patients with CDH. Most
published guidelines are the personal experience of the
authors or the summary of the available evidences. Prob-
ably it is the reason for heterogeneity in treatment of
patients with NDPH in most case series (including ours).
A few authors suggest that aggressive intravenous
therapy for intractable CDH is more cost- and time-effec-
tive mode of treatment [18]. Krusz suggests that intrave-
nous therapy may help in breaking a long, unremitting
cycle of CDH. Intravenous sodium valproate is one of the
safest intravenous drugs used for the various headache
disorders and its effects have been demonstrated in both
intractable acute attack and chronic daily headaches [19–
21]. In one open-label study, intravenous valproate was
effective in a number of primary headache disorders
(including CDH) [21]. Improvement in headache was noted
by 80 % patients with CDH by intravenous valproate in
another open-label study [20].
Various studies have demonstrated the beneficial effects
of injectable steroids on acute intractable attack of migraine
and other headache disorders. Anecdotal evidences suggest
that intravenous steroid for the short term may effective
even in CDH patients [17, 18]. A recent meta-analysis
suggests that addition of steroid to the standard therapy for
the management of acute migraine headache may decrease
the incidence of the recurrence of headaches [22]. The dose
and duration of steroids are highly variable. Most authors
used steroids for a few days to about 2 weeks. Bonuccelli
et al. [23] gave injectable dexamethasone (with amitripty-
line) for 2 weeks in patients with CDH. Trucco et al. [24]
gave intravenous dexamethasone (8 mg daily) (with other
drugs) for 7–15 days. The authors [24] suggest that a higher
dose or intravenous route (of steroids) may be required for
patients with CDH/medication overused headaches.
Intravenous MPS is generally considered as safe as
majorities of the side effects are transient and self-limiting
and do not require specific treatment [25].
Our observation showed a lower percentage of medica-
tion overuse (13 %). This observation was similar to that of
Kung et al.’s case series [6] where medication overuse was
noted in only in 8.7 % patients. However, a few recent
observations reported higher proportion of medication
overuse in patients with NDPH. Robbins et al.’s [3] reported
medication overuse in about 45 % patients. In Peng et al.’s
series [2], medication overuse was noted in about 35 %
patients with NDPH. The factors predicting development of
the medication overused headache have not been explored
in the literature. However, the presence of such wide vari-
ability of prevalence of medication overuse headache in
patients with NDPH suggests multifactorial involvement.
Chronic daily headache has been linked to various
comorbid psychiatric conditions. Associated psychiatry
disorders can lead to poor response to therapy. However,
there are very few studies in patients with NDPH in which
psychiatric evaluation was performed. Robbins et al.’s
reported self-reported anxiety and self-reported depression
in about one-third of the patients. In Peng et al. case series
[2], psychiatry comorbidities were noted in more than half
of the patients. However, in both case series, associated
psychiatric comorbidities were not related with the out-
comes. Detail psychiatric evaluations were not done in our
patients. Self-reported depression and anxiety were noted
by a few patients in our case series (19 and 16 % respec-
tively) (Table 1). No association was noted between clin-
ical outcomes and self-reported depression and anxiety.
However, as comorbid psychiatry disorders are known to
have a poor response to therapy, better outcome in our case
series may be because of low rates of comorbid depression
and anxiety.
The etiology of NDPH is poorly defined. About 40–60 %
patients recognize triggers at the onset of the headache [2, 3,
5, 12]. Our 56 % patients had recognized triggers at the
onset of NDPH. Besides infectious etiology (29 %), other
triggers in our patients were injury, stress, surgery, and post
partum state. Injury was reported as a trigger by seven (11 %)
patients. Three patients had mild head trauma. A possibility of
chronic post-traumatic headache attributed to mild head injury
(ICHD-II code 5.2.2) [4] exists in these patients. However, it
was less likely as none of the patients had symptoms and/or
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signs suggestive of concussion (a must to fulfill the criteria of
5.2.2) [4]. Although most case series did not report head
trauma as a trigger, it was the second most common inciting
factor (23 %) in Mack’s series [12]. Surgery and stress are two
important triggers for the development of NDPH. We think
injury or trauma may be analogous to surgery. Moreover,
injury itself may produce stress (another trigger for NDPH).
Most case series excludes the injury as triggers for NDPH.
However, our case series and Mack’s observation suggest that
injury may be a trigger for the development of NDPH, and
mechanisms responsible for it may be entirely different from
that of post-traumatic headache. Though statistically not sig-
nificant, patients with recognized triggers showed better out-
come. A study with larger sample of patients is required to
confirm the observations.
Ethnic and geographical variation should also be taken
into consideration for such type of observation, especially
for post infectious variant, as infectious agents vary with
the environmental factors. All patients received drugs
before reporting to us. Therefore, we cannot rule out a
possibility of delayed response of previously used drugs in
a few patients. Therefore, our observations should be
judged very cautiously.
Limitation of the study
It is a retrospective study and possibilities of unrecognized
selection bias and recall bias exist. There was a low recall
of the headache onset day compared to other NDPH series.
Therefore, a possibility of recall bias about onset of
headache may be high in our case series. In addition,
headache management and treatment were not standard-
ized. Besides these, we cannot rule out even the possibility
of other cause of headache (secondary), as full evaluation
for secondary headache was not done (contrast enhanced
MRI and MRV were not done in each patient). The patients
in our study were seen in an adult tertiary neurology clinic.
Therefore, our observations cannot be generalized as our
sample of patients may not truly represent patients with
new onset headaches due to referral and other biases.
Despite a number of limitations in the study, the positive
outcome suggests that further research is necessary.
Conclusion
Migrainous features might be the common features in
patients with NDPH, however, its presence should be
judged cautiously in patients with past history of episodic
headache, especially episodic migraine. Our observations
hint that early intravenous therapy may prevent chronification.
However, we would not like to draw any conclusion as it was a
retrospective, open-label, and uncontrolled study.
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